Literature DB >> 32298471

Interventional Pharmacoeconomics: A Novel Mechanism for Unlocking Value.

Anthony V Serritella1, Garth W Strohbehn1,2, Daniel A Goldstein2,3,4,5, Allen S Lichter2, Mark J Ratain1,2.   

Abstract

Cancer care's sustainability is challenged by drug expenditures. In the absence of systemic change, innovation is needed to curtail drug costs. Interventional pharmacoeconomics (IVPE) utilizes clinical research to identify safe, efficacious, cost-conscious dosing regimens to extract maximum value from expensive therapies. Strategies include de-escalation of dosage, treatment duration and administration frequency, and substitution with therapeutic alternatives. In this review, we discuss how IVPE strategies have been successfully used and could be implemented going forward.
© 2020 The Authors Clinical Pharmacology & Therapeutics © 2020 American Society for Clinical Pharmacology and Therapeutics.

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32298471     DOI： 10.1002/cpt.1853

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


  7 in total

1.  Adoption of Extended-Interval Dosing of Single-Agent Pembrolizumab and Comparative Effectiveness vs Standard Dosing in Time-to-Treatment Discontinuation.

Authors:  Garth W Strohbehn; Robert Holleman; Jennifer Burns; Mandi L Klamerus; Michael J Kelley; Eve A Kerr; Nithya Ramnath; Timothy P Hofer
Journal:  JAMA Oncol       Date:  2022-09-22       Impact factor: 33.006

Review 2.  Boosting the oral bioavailability of anticancer drugs through intentional drug-drug interactions.

Authors:  Eric D Eisenmann; Zahra Talebi; Alex Sparreboom; Sharyn D Baker
Journal:  Basic Clin Pharmacol Toxicol       Date:  2021-06-28       Impact factor: 4.080

3.  Clinical research in oncology: in memory of Professor Gordon McVie.

Authors:  Ian F Tannock
Journal:  Ecancermedicalscience       Date:  2022-01-13

4.  Alternative trastuzumab dosing strategies in HER2-positive early breast cancer are associated with patient out-of-pocket savings.

Authors:  Po-Hung Hsieh; Alec J Kacew; Marie Dreyer; Anthony V Serritella; Randall W Knoebel; Garth W Strohbehn; Mark J Ratain
Journal:  NPJ Breast Cancer       Date:  2022-03-14

Review 5.  Barriers and Facilitators of Pharmacoeconomic Studies: A Review of Evidence from the Middle Eastern Countries.

Authors:  Abdulaziz Ibrahim Alzarea; Yusra Habib Khan; Abdullah Salah Alanazi; Muhammad Hammad Butt; Ziyad Saeed Almalki; Abdullah K AlAhmari; Saud Alsahali; Tauqeer Hussain Mallhi
Journal:  Int J Environ Res Public Health       Date:  2022-06-27       Impact factor: 4.614

Review 6.  Dose optimisation and scarce resource allocation: two sides of the same coin.

Authors:  Garth Strohbehn; Govind Persad; William F Parker; Srinivas Murthy
Journal:  BMJ Open       Date:  2022-10-12       Impact factor: 3.006

7.  COVIDOSE: A Phase II Clinical Trial of Low-Dose Tocilizumab in the Treatment of Noncritical COVID-19 Pneumonia.

Authors:  Garth W Strohbehn; Brian L Heiss; Sherin J Rouhani; Jonathan A Trujillo; Jovian Yu; Alec J Kacew; Emily F Higgs; Jeffrey C Bloodworth; Alexandra Cabanov; Rachel C Wright; Adriana K Koziol; Alexandra Weiss; Keith Danahey; Theodore G Karrison; Cuoghi C Edens; Iazsmin Bauer Ventura; Natasha N Pettit; Bhakti K Patel; Jennifer Pisano; Mary E Strek; Thomas F Gajewski; Mark J Ratain; Pankti D Reid
Journal:  Clin Pharmacol Ther       Date:  2020-12-10       Impact factor: 6.903
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.